Company Profile: Bayer

Company Profile: Bayer

  • December 2017 •
  • 48 pages •
  • Report ID: 5336385 •
  • Format: PDF
Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

Snapshot
Overview – Bayer’s prescription drug sales will experience modest growth up to 2026.
Out to 2022 – Bayer’s prescription drug sales will grow rapidly out to 2022, reaching total sales of $22.8bn.
Out to 2026 – Following major patent expiries in 2023, sales will marginally decline to $22.5bn in 2026.
Pipeline – Diabetic nephropathy treatment finerenone set for approval in 2020.
Events – Completion of Monsanto acquisition, and updates to Xarelto’s label.

Highlights
Bayer’s prescription drug sales will experience modest growth up to 2026.
Genitourinary remains a key therapy area, despite little RandD involvement. Sales of contraceptive franchises Yaz and Mirena will drive sales in the segment.
Internal cardiovascular research will provide long-term sales growth.
Bayer’s in-licensing strategy will continue to have moderate success.

Model updates
Added vilaprisan
ODM-201 changed to darolutamide
Copanlisib changed to Aliqopa.

Analysis structure
Explore and visualize revenue dynamics in Bayer’s portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections.

Company context
How is Bayer strategically poised out to 2026?
What are Bayer’s key strengths, weaknesses, opportunities, and threats?
What are Bayer’s key catalysts during the current year?

Facts and figures
What is Bayer’s forecasted sales performance out to 2026?
What is the revenue trajectory of Bayer’s current top 10 products out to 2026?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of Bayer based on the lifecycle of its products?

Key therapy areas
Why will specific therapy areas experience the largest growth and decline?
What are the detailed competitive dynamics at play in Bayer’s important therapeutic markets?
How is Bayer adapting strategically to internal and external headwinds?